sábado, 2 de septiembre de 2017

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. - PubMed - NCBI

2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

Wu YL1, Wang CL2, Sun Y3, Liao ML4, Guan ZZ5, Yang ZM6, Zhou QH7, Lu S4, Cheng Y8, Liu XQ9, Zhang XC1, Zhou C10, Wang J11, Zhou Q1, Song Y12, Han BH13, Ma ZY14, Yang F15, Wang Q16, Chuai SK17, Shao Y18,19, He W20, Zhu G21, Xiong L22, Wang JJ23, Chen KN24, Zhang L5, Mao WM25, Ma SL26, Feng JF27, Yang XN1, Xu L28, Chen G1, Zhao J29, Song QB30, Shen-Tu Y4, Qiao GB31, Yu D32, Yu SY33, Hu Y34, Chen M35, Chen GY36, Fan Y37, Zhang HL38, Liang J11, Zhu GY39, Cui JW40, Yang JJ1, Zhao Q41, Zhao MF42, Lu Y43, Chang JH44, Li JL11, Yang Y45, Hu J46, Gu CD47, Zhang YC1, Zhong WZ1.

Author information

Abstract

The diagnosis and treatment of lung cancer have evolved into the era of precision medicine. Liquid biopsy, a minimally invasive approach, has emerged as a promising practice in genetic profiling and monitoring of lung cancer. Translating liquid biopsy from bench to bedside has encountered various challenges, including technique selection, protocol standardisation, data analysis and cost management. Regarding these challenges, the 2016 Chinese Lung Cancer Summit expert panel organised a trilateral forum involving oncologists, clinicians, clinical researchers, and industrial expertise on the 13th Chinese Lung Cancer Summit to formally discuss these controversies. Six consensuses were reached to guide the use of liquid biopsy and perform precision medicine in both clinic and research.